InterAx Biotech AG, PARK InnovAARE, Villigen, 5234, Switzerland.
Laboratory of Biomolecular Research, Paul Scherrer Institute, Villigen, 5232, Switzerland.
Sci Rep. 2019 Jan 24;9(1):439. doi: 10.1038/s41598-018-36881-4.
Arrestin-1 desensitizes the activated and phosphorylated photoreceptor rhodopsin by forming transient rhodopsin-arrestin-1 complexes that eventually decay to opsin, retinal and arrestin-1. Via a multi-dimensional screening setup, we identified and combined arrestin-1 mutants that form lasting complexes with light-activated and phosphorylated rhodopsin in harsh conditions, such as high ionic salt concentration. Two quadruple mutants, D303A + T304A + E341A + F375A and R171A + T304A + E341A + F375A share similar heterologous expression and thermo-stability levels with wild type (WT) arrestin-1, but are able to stabilize complexes with rhodopsin with more than seven times higher half-maximal inhibitory concentration (IC) values for NaCl compared to the WT arrestin-1 protein. These quadruple mutants are also characterized by higher binding affinities to phosphorylated rhodopsin, light-activated rhodopsin and phosphorylated opsin, as compared with WT arrestin-1. Furthermore, the assessed arrestin-1 mutants are still specifically associating with phosphorylated or light-activated receptor states only, while binding to the inactive ground state of the receptor is not significantly altered. Additionally, we propose a novel functionality for R171 in stabilizing the inactive arrestin-1 conformation as well as the rhodopsin-arrestin-1 complex. The achieved stabilization of the active rhodopsin-arrestin-1 complex might be of great interest for future structure determination, antibody development studies as well as drug-screening efforts targeting G protein-coupled receptors (GPCRs).
抑制蛋白-1 通过形成瞬态视紫红质-抑制蛋白-1 复合物来使激活和磷酸化的光感受器视紫红质脱敏,该复合物最终降解为视蛋白、视网膜和抑制蛋白-1。通过多维筛选装置,我们鉴定并组合了抑制蛋白-1 突变体,这些突变体在高离子盐浓度等恶劣条件下与光激活和磷酸化的视紫红质形成持久复合物。两个四重突变体,D303A+T304A+E341A+F375A 和 R171A+T304A+E341A+F375A,与野生型(WT)抑制蛋白-1 具有相似的异源表达和热稳定性水平,但能够稳定与视紫红质形成的复合物,与 WT 抑制蛋白-1 相比,NaCl 的半最大抑制浓度(IC)值高出七倍以上。与 WT 抑制蛋白-1 相比,这些四重突变体还具有更高的与磷酸化视紫红质、光激活视紫红质和磷酸化视蛋白的结合亲和力。此外,评估的抑制蛋白-1 突变体仍然仅特异性地与磷酸化或光激活的受体状态结合,而对受体的非活性基础状态的结合没有明显改变。此外,我们提出了 R171 在稳定无活性抑制蛋白-1 构象以及视紫红质-抑制蛋白-1 复合物方面的新功能。这种对活性视紫红质-抑制蛋白-1 复合物的稳定可能对未来的结构确定、抗体开发研究以及针对 G 蛋白偶联受体(GPCR)的药物筛选工作具有重要意义。